MedTrace Logo

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

NCT00255346 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-12-30

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.

Conditions

Interventions

DRUG

Dasatinib (BMS-354825)

70 mg orally twice daily

Sponsors & Collaborators

Principal Investigators

  • Hagop M Kantarjian, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-15
Primary Completion
2017-03-03
Completion
2017-03-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255346 on ClinicalTrials.gov